An ongoing clinical trial NCT03363217/TRAM-01 aims to study trametinib as a monotherapy in a basket trial involving four groups of progressive tumors (KIAA1540-BRAF fusion, NF1-associated plexiform neurofibromas, NF1-associated other gliomas, and other MAPK-ERK pathway–activated gliomas) (71). Here, NF1 is linked to plexiform neurofibroma.